摘要
侵犯胸壁的非小细胞肺癌(NSCLC)曾被认为预后不佳,肺部切除合并胸壁切除与重建及淋巴结清扫为主要手术方式。但术前新辅助治疗、手术与重建方式及术后辅助治疗尚无统一标准。近年来,随着手术切除方式及胸壁重建技术不断进步,肿瘤整体切除已经不再是挑战,靶向及免疫治疗成为新辅助治疗/术后辅助治疗研究的新方向,有望进一步提升侵犯胸壁的NSCLC患者的预后。现对侵犯胸壁可切除NSCLC的手术及重建方式、术前新辅助及术后辅助治疗方式进行总结,以期为此类患者的治疗决策提供帮助。
Non-small cell lung cancer(NSCLC)invading the chest wall was once considered to have poor prognosis.Pulmonary resection combined with lymph node dissection,chest wall resection and chest wall reconstruction have been the main surgical methods.However,unified standard has not been determined for preoperative neoadjuvant therapy,surgical and reconstruction methods,and postoperative adjuvant therapy.In recent years,with the development of surgical resection methods and chest wall reconstruction technology,complete tumor resection is no longer a challenge.Tumor targeted therapy and immunotherapy have become new directions for neoadjuvant therapy and postoperative adjuvant therapy research,which is expected to further improve the prognosis of patients with NSCLC invading the chest wall.This article summarizes the latest research progress in surgical and reconstruction methods,preoperative neoadjuvant and postoperative adjuvant therapy for patients with resectable non-small cell lung cancer invading the chest wall,in order to provide help for the treatment decision of patients with this type of cancer.
作者
梁骁
王磊
姜涛
Liang Xiao;Wang Lei;Jiang Tao(Department of Thoracic Surgery,Tangdu Hospital,Air Force Medical University,Xi’an 710038,China)
出处
《中华胸部外科电子杂志》
2022年第3期157-163,共7页
CHINESE JOURNAL OF THORACIC SURGERY：Electronic Edition
关键词
侵犯胸壁
非小细胞肺癌
胸壁重建
Chest wall invasion
Non-small cell lung cancer
Chest wall reconstruction
